Science · 2004 · 202 citations · 13 references
Life SciencesBiochemistryMedicinal ChemistryDrug DiscoveryNeurodegenerationProtein-protein InteractionsAlzheimer DiseaseAmyloid FormationLigand BindingMolecular ChaperonesProtein AggregationProtein Aggregation DisordersAggregationAmyloid Beta AggregationAmyloid InhibitionChaperone-substrate InteractionsProtein Aggregation InhibitionProtein Aggregation InhibitorsSteric BulkTherapeutic Targeting Of Amyloid
Protein aggregation is involved in the pathogenesis of neurodegenerative diseases and hence is considered an attractive target for therapeutic intervention. However, protein-protein interactions are exceedingly difficult to inhibit. Small molecules lack sufficient steric bulk to prevent interactions between large peptide surfaces. To yield potent inhibitors of beta-amyloid (Abeta) aggregation, we synthesized small molecules that increase their steric bulk by binding to chaperones but also have a moiety available for interaction with Abeta. This strategy yields potent inhibitors of Abeta aggregation and could lead to therapeutics for Alzheimer's disease and other forms of neurodegeneration.
13
Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis
Rakez Kayed, Elizabeth Head, Jennifer L. Thompson et al. · Science · 2003 · 4.1K citations
Controlling Signal Transduction with Synthetic Ligands
David M. Spencer, Thomas J. Wandless, Stuart L. Schreiber et al. · Science · 1993 · 854 citations
Convergent Solutions to Binding at a Protein-Protein Interface
Warren L. DeLano, Mark Ultsch, Abraham M. de et al. · Science · 2000 · 682 citations